Difference between revisions of "Part:BBa K5059000"
Line 21: | Line 21: | ||
<center> | <center> | ||
<img src="https://static.igem.wiki/teams/5059/pathway.webp" style="width: 600px; height:auto"> | <img src="https://static.igem.wiki/teams/5059/pathway.webp" style="width: 600px; height:auto"> | ||
− | <figcaption>Figure 1: Metabolic Pathway for Producing Ursolic Acid in | + | <figcaption>Figure 1: Metabolic Pathway for Producing Ursolic Acid in Yeast</figcaption> |
</center> | </center> | ||
</html> | </html> |
Revision as of 13:17, 1 October 2024
Alpha-Amyrin Synthase (AAS)
This sequence resembles the MdOSC1 variant of the alpha-amyrin synthase from Malus domestica. Alpha-amyrin synthase (AAS) converts 2,3-oxidosqualene to alpha-amyrin, the precursor for ursolic acid in the mevalonate pathway [1]. Since S. cerevisiae doesn't contain AAS, we integrated this sequence into its genome to successfully produce ursolic acid. We also added a 6xHis tag at the end of the sequence to enable Ni-NTA chromatography.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Usage and Biology
Ursolic acid has gained traction recently as a potential therapeutic agent. Preliminary studies have been done on ursolic acid, determining its therapeutic potential for cancer, liver disease, and obesity, among other health benefits [2]. There is particular interest in ursolic acid's properties in fighting cancer, as it is an antioxidant and anti-inflammatory agent. Clinical trials are currently underway to test its use in cancer-treating drugs. However, the current method for ursolic acid extraction from fruits, such as apples and loquats, is inefficient, environmentally taxing, and expensive. By engineering S. cerevisiae to produce ursolic acid, the traditional method for its extraction can be bypassed by utilizing the pathway shown below.
Within this pathway, AAS is the first enzyme required to catalyze ursolic acid production. Specifically, it catalyzes the conversion of 2,3-oxidosqualene to alpha-amyrin, which is the direct precursor for ursolic acid through the action of Cytochrome P450, which is activated via Cytochrome P450 reductase donating an electron from NADPH to it.
Functionality
Catalytic Efficiency
Substrate | Product | Km (µM) | kcat (min^-1) | kcat/Km (min^-1/µM) |
---|---|---|---|---|
1. 2,3-oxidosqualene | alpha-amyrin | 50.07 | 43.4 | 0.87 |
2. alpha-amyrin | Ursolic Acid | 24.5 | 35 | 1.43 |
References
[1] Jia, N., Li, J., Zang, G., Yu, Y., Jin, X., He, Y., Feng, M., Na, X., Wang, Y., & Li, C. (2024). Engineering Saccharomyces cerevisiae for high-efficient production of ursolic acid via cofactor engineering and acetyl-CoA optimization. Biochemical Engineering Journal, 203, 109189. https://doi.org/10.1016/j.bej.2023.109189
[2] Alam, M., Ali, S., Ahmed, S., Elasbali, A. M., Adnan, M., Islam, A., Hassan, Md. I., & Yadav, D. K. (2021). Therapeutic Potential of Ursolic Acid in Cancer and Diabetic Neuropathy Diseases. International Journal of Molecular Sciences, 22(22), 12162. https://doi.org/10.3390/ijms222212162
[3] Yu, Y., Chang, P., Yu, H., Ren, H., Hong, D., Li, Z., Wang, Y., Song, H., Huo, Y., & Li, C. (2018). Productive Amyrin Synthases for Efficient α-Amyrin Synthesis in Engineered Saccharomyces cerevisiae. ACS Synthetic Biology, 7(10), 2391–2402. https://doi.org/10.1021/acssynbio.8b00176